Breaking News

Catalent Acquires Relthy in Brazil

October 10, 2013

Expands South American Softgel Business

Catalent Pharma Solutions has acquired Relthy Laboratórios in Brazil, expanding its softgel business and operations in South America. Relthy produces softgel encapsulated Vitamin, Mineral and Supplement (VMS) products, as well as prescription and OTC products for the Brazilian market. Relthy has 350 employees and a production capacity of two billion capsules per year. Relthy’s management team will join Catalent. Financial terms were not disclosed.
 
The acquisition provides Catalent entry into the VMS nutritional market and expands its primary and secondary packaging capabilities in Brazil. Relthy is Catalent’s 11th softgel facility in its global network and will complement its existing pharmaceutical and OTC focused South American facilities in Sorocaba, Brazil and Buenos Aires, Argentina.
 
“This investment will benefit our domestic and international customers as it draws on both parties’ complementary capabilities to holistically address market needs,” said Dr. Aris Gennadios, president of Softgel Technologies, Catalent Pharma Solutions. “Brazil represents a key strategic location for Catalent and its customers, and this acquisition will create significant growth opportunities.”
 
Paulo Vianna, chairman and chief executive officer of Relthy Laboratórios, said, “The deal brings together Catalent’s expertise in OTC and Rx manufacturing, deep regulatory compliance knowledge, its global R&D resources and advanced capabilities and combines these with our existing domestic customer base and proven ability to respond to local customer needs and market requirements.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important